Literature DB >> 22054913

Patients with atrial fibrillation in a primary care setting: Val-FAAP study.

Vivencio Barrios1, Alberto Calderón, Carlos Escobar, Mariano de la Figuera.   

Abstract

OBJECTIVE: To assess the clinical characteristics of patients with atrial fibrillation in the primary care setting.
METHODS: This was a 2-phase, cross-sectional, multicenter study: phase A assessed the proportion of atrial fibrillation patients assisted in primary care over 5 days; phase B analyzed atrial fibrillation patients' clinical characteristics and management.
RESULTS: In phase A, 119 526 subjects (age 52.9 [15.2] years; 40.9% male) received primary care in participating centers; 6.1% had atrial fibrillation. This proportion increased with age, hypertension, and male sex. In phase B, we analyzed 3287 atrial fibrillation patients (age 71.9 [10.1] years; 52.3% male). Risk factors were hypertension (92.6%), hypercholesterolemia (70.6%), related cardiovascular disease, heart failure (21.3%), and ischemic heart disease (20.9%). Permanent atrial fibrillation was the most frequent type of atrial fibrillation (45.3%). Age and cardiac and renal diseases were related to permanent atrial fibrillation development. Although more than two-thirds of patients had a CHADS(2) score ≥2, about one-third of them were not taking anticoagulants; by contrast, 46.8% of patients with CHADS(2)=0 were taking oral anticoagulants.
CONCLUSIONS: In primary care, 6.1% of patients had atrial fibrillation. Patients with atrial fibrillation had high comorbidity. Anticoagulant treatment is far from optimal for atrial fibrillation patients in primary care.
Copyright © 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22054913     DOI: 10.1016/j.recesp.2011.08.008

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  19 in total

Review 1.  Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal.

Authors:  Antoni Martínez-Rubio; Mario DiazNuila Alcazar; Anna Soria Cadena; Roger Martínez-Torrecilla
Journal:  Eur Cardiol       Date:  2016-12

2.  Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records.

Authors:  Marc Casajuana; Maria Giner-Soriano; Albert Roso-Llorach; Cristina Vedia; Concepció Violan; Rosa Morros
Journal:  Eur J Health Econ       Date:  2018-02-20

3.  Atrial fibrillation and hypertension: do new anticoagulants change the matter?

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderon
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-27       Impact factor: 3.738

4.  Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database.

Authors:  Pierre Sabouret; Leyla Depret-Bixio; François-Emery Cotte; Pierre Marie; Nabil Bedira; Patrick Blin
Journal:  Clin Res Cardiol       Date:  2014-05-15       Impact factor: 5.460

5.  Aliskiren: a potential antiarrhythmic drug?

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderon
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-01-24       Impact factor: 3.738

6.  Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.

Authors:  Carmen Suárez Fernández; Suárez Fernández; Francesc Formiga; Miguel Camafort; María Cepeda Rodrigo; Jose Cepeda Rodrigo; Jesús Díez-Manglano; Antonio Pose Reino; Pose Reino; Gregorio Tiberio; Jose María Mostaza
Journal:  BMC Cardiovasc Disord       Date:  2015-11-04       Impact factor: 2.298

7.  Identification of Atrial Fibrillation-Associated Genes ERBB2 and MYPN Using Genome-Wide Association and Transcriptome Expression Profile Data on Left-Right Atrial Appendages.

Authors:  Xiangguang Meng; Yali Nie; Keke Wang; Chen Fan; Juntao Zhao; Yiqiang Yuan
Journal:  Front Genet       Date:  2021-06-30       Impact factor: 4.599

8.  Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.

Authors:  Jan Murin; Lisa Naditch-Brûlé; Sandrine Brette; Chern-En Chiang; James O'Neill; P Gabriel Steg
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

9.  Risk factors and therapeutic coverage at 6 years in patients with previous myocardial infarction: the CASTUO study.

Authors:  Francisco Javier Félix-Redondo; Luis Lozano Mera; Luciano Consuegra-Sánchez; Fernando Giménez Sáez; Francisco Javier Garcipérez de Vargas; José María Castellano Vázquez; Daniel Fernández-Bergés
Journal:  Open Heart       Date:  2016-02-26

10.  Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database.

Authors:  Maria Giner-Soriano; Cristina Vedia Urgell; Albert Roso-Llorach; Rosa Morros; Dolors Capellà; Xavier Castells; Ignacio Ferreira-González; Amelia Troncoso Mariño; Eduard Diògene; Josep M Elorza; Marc Casajuana; Bonaventura Bolíbar; Concepció Violan
Journal:  BMJ Open       Date:  2016-01-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.